Shots: The P-III YOSEMITE & RHINE studies involve assessing faricimab (6mg at personalized dosing intervals of up to 4mos. and at fixed 2mos. intervals) vs aflibercept (2mg, fixed 2mos. intervals) in 1891 patients with DME The P-III TENAYA & LUCERNE studies assessing faricimab (6mg administered at fixed intervals of every 2,3 & 4mos. based on […]Read More
Shots: The companies collaborated to evaluate ruxolitinib in combination with CK0804 in patients with MF and plan to initiate a P-Ib study. Incyte will fund the study while operationalized by Cellenkos Cellenkos to receive $20M as licensing fee, ~$294.5M as development, regulatory and commercialization milestones along with royalties on sales of therapies, if approved. Incyte […]Read More
Shots: The P-III YOSEMITE & RHINE studies assessing faricimab vs aflibercept in 1891 people living with DME. The studies include 3 treatment arms: faricimab (6mg) administered at personalized dosing intervals of ~16wks and at fixed 8wks. intervals & aflibercept (2mg) at fixed 8wks. intervals The studies met its 1EPs i.e faricimab in both the doses […]Read More
Shots: The initiation of the ENSEMBLE trial follows positive interim results of P-I/IIa study demonstrating the safety and immunogenicity of JNJ-78436735 following a single vaccination. The results have been submitted to medRxiv and expected to be published imminently The P-III ENSEMBLE study is designed to assess the safety & efficacy of a single vaccine dose […]Read More
The concept of telemedicine has evolved in recent years. As people are demanding easier ways to avail of medical treatment and diagnosis, there have been several advances in telemedicine. Telemedicine is a method that involves providing clinical services through a distance. Through telemedicine, the user doesn’t necessarily have to be present at the hospital or […]Read More
Shots: UCB to receive $120M and is eligible to receive $2B as cost reimbursement, development, and commercial milestones as well as royalties on sales of the therapies, if Roche proceeds the clinical development. Roche to get an exclusive license to develop and commercialize UCB0107 for AD UCB to fund and perform a POC study in […]Read More
Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected […]Read More
Shots: BioNTech to receive $185M up front, including $72M cash & $113M equity investment, up to $563M as milestone making a total deal value $748M. The companies will equally share the development cost while Pfizer will fund 100% of development cost at the initial level and BioNTech will repay Pfizer its 50% share during the […]Read More
Shots: Medopod’s RPM platform will be available for NHS Trusts across the UK as well as global healthcare providers that allow doctors to track patient’s data, symptom progression and flag patients with worsening symptoms, both inside and outside of clinical settings Patients will use the app to share their personal data such as temperature, respiration […]Read More
Shots: WHO convoke global research and innovation forum to be held on Feb 11-12, 2020 in Geneva for mobilization of international action in response to the coronavirus (2019-nCoV) and is organized in collaboration with the Global Research Collaboration for Infectious Disease Preparedness The forum will involve scientist, public health agencies, ministries of health and research […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
